- Home
- LCTX vs VKI Comparison
LCTX vs VKI Comparison
Compare LCTX & VKI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- VKI
- Stock Information
- Founded
- LCTX 1990
- VKI 1993
- Country
- LCTX United States
- VKI United States
- Employees
- LCTX N/A
- VKI N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- VKI Finance Companies
- Sector
- LCTX Health Care
- VKI Finance
- Exchange
- LCTX Nasdaq
- VKI Nasdaq
- Market Cap
- LCTX 405.4M
- VKI 390.8M
- IPO Year
- LCTX N/A
- VKI N/A
- Fundamental
- Price
- LCTX $1.76
- VKI $8.90
- Analyst Decision
- LCTX Strong Buy
- VKI
- Analyst Count
- LCTX 4
- VKI 0
- Target Price
- LCTX $4.25
- VKI N/A
- AVG Volume (30 Days)
- LCTX 2.6M
- VKI 112.8K
- Earning Date
- LCTX 11-06-2025
- VKI 01-01-0001
- Dividend Yield
- LCTX N/A
- VKI 4.52%
- EPS Growth
- LCTX N/A
- VKI N/A
- EPS
- LCTX N/A
- VKI N/A
- Revenue
- LCTX $10,816,000.00
- VKI N/A
- Revenue This Year
- LCTX N/A
- VKI N/A
- Revenue Next Year
- LCTX $176.00
- VKI N/A
- P/E Ratio
- LCTX N/A
- VKI N/A
- Revenue Growth
- LCTX 24.05
- VKI N/A
- 52 Week Low
- LCTX $0.37
- VKI $7.07
- 52 Week High
- LCTX $2.09
- VKI $8.98
- Technical
- Relative Strength Index (RSI)
- LCTX 50.62
- VKI 48.66
- Support Level
- LCTX $1.77
- VKI $8.92
- Resistance Level
- LCTX $1.99
- VKI $9.09
- Average True Range (ATR)
- LCTX 0.15
- VKI 0.09
- MACD
- LCTX -0.01
- VKI -0.01
- Stochastic Oscillator
- LCTX 42.27
- VKI 32.14
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About VKI Invesco Advantage Municipal Income Trust II of Beneficial Interest (DE)
Invesco Advantage Municipal Income Trust II is a diversified, closed-end management investment company. The investment objective of the company is to provide common shareholders with a high level of current income exempt from federal income tax, consistent with preservation of capital.